Sponsor or institution
Clinical trials and research at CatalYm GmbH
As of November 12, 2026, Find a Trial lists 4 clinical trials run by CatalYm GmbH that are recruiting, at sites in 15 countries (most in Germany (4), Italy (4), Spain (4)). By phase: Phase 2 (3), Phase 2/3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 15Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Visugromab plus nivolumab, with or without docetaxel, for second-line treatment of metastatic non-squamous non-small cell lung cancer | Phase 2 | Birmingham, Alabama and 35 other locations | Recruiting | Nov 24, 2025 |
| Visugromab plus Nivolumab and Lenvatinib versus Placebo plus Lenvatinib for unresectable or metastatic hepatocellular carcinoma after anti–PD-(L)1 therapy | Phase 2 | Irvine, California and 28 other locations | Recruiting | Oct 21, 2025 |
| Visugromab for cancer-related wasting and unintended weight loss | Phase 2/3 | Norwich, Connecticut and 78 other locations | Recruiting | Aug 8, 2025 |
| Visugromab added to first-line immunochemotherapy for metastatic non-squamous NSCLC | Phase 2 | Birmingham, Alabama and 50 other locations | Recruiting | Aug 1, 2025 |
All recruiting trials (4)
-
Visugromab plus nivolumab, with or without docetaxel, for second-line treatment of metastatic non-squamous non-small cell lung cancer
This trial tests whether adding the anti-GDF-15 antibody visugromab to nivolumab, with or without docetaxel, helps people with metastatic non-squamous NSCLC whose cancer progressed after first-line treatment that included a checkpoint inhibitor.
-
Visugromab plus Nivolumab and Lenvatinib versus Placebo plus Lenvatinib for unresectable or metastatic hepatocellular carcinoma after anti–PD-(L)1 therapy
This trial will test whether adding visugromab and nivolumab to lenvatinib helps people with unresectable or metastatic liver cancer whose disease progressed after an anti–PD-(L)1 treatment.
-
Visugromab for cancer-related wasting and unintended weight loss
This trial will test whether visugromab helps people with advanced cancer and unintentional weight loss (cachexia) gain weight, have a better appetite, and improve mobility compared with a placebo.
-
Visugromab added to first-line immunochemotherapy for metastatic non-squamous NSCLC
This trial tests whether adding visugromab to standard immunochemotherapy (pembrolizumab, pemetrexed, carboplatin) helps people with newly diagnosed metastatic non-squamous NSCLC who do not have targetable mutations.
Quick answers
How many clinical trials run by CatalYm GmbH are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 15 countries. The most sites are in Germany (4 trials), Italy (4 trials), Spain (4 trials), United States (4 trials), Poland (3 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.